样式: 排序: IF: - GO 导出 标记为已读
-
Higher expression of HERV-K was observed in peripherial B Lymphocytes of Leukemia and Lymphoma Patients. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-11-27 Tianfu Li,Kun Qian,Jingwan Han,Yongjian Liu,Lei Jia,Xiaolin Wang,Tianyi Li,Bohan Zhang,Jingyun Li,Hanping Li,Liping Dou,Lin Li
Haematological malignant tumors (HMTs) are serious diseases that threaten human health and life with high mortality. Therefore, it is necessary to develop novel strategies for diagnosis and treatment. Human endogenous retroviruses (HERVs) have recently attracted increasing attention as potential targets for cancer diagnosis and therapy. In this study, we explored the association between HERV-K expression
-
Near-full-length genome analysis of a HIV-1 CRF01_AE/B recombinant strain among men who have sex with men in Chengde City, China. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-11-19 Shuofan Dong,Xinli Lu,Yingying Wang,Ning An,Meng Liu,Yan Li,Qi Li
The unique recombinant form (URF) of HIV is formed by multiple subtypes which are co-circulating in some area, and the number of HIV recombinants is on the increase worldwide. In this study, we identified a URF named 2019638, composed of CRF01_AE and subtype B, in a man who has sex with men (MSM) in Qinhuangdao, Hebei province, China. The near-full-length genome (NFLG) sequence was confirmed to be
-
Mitochondrial Metabolism in Alveolar Macrophages of Patients Infected with HIV, Tuberculosis, and HIV/Tuberculosis. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-11-14 Ling Zhang,Miaotian Cai,Bin Su,Yingmin Ma,Yulin Zhang
Tuberculosis (TB) is one of the most common opportunistic infections and is a leading cause of mortality in patients with HIV and AIDS. HIV infection causes serious defects in the host immune system and increases the risk of active TB. TB infection promotes HIV replication and aggravates host damage in patients with HIV/AIDS. Alveolar macrophages (AMs) are essential immune cells during TB and HIV infections
-
Perceived Risks and Benefits and Frequency of Cannabis Use Among People with HIV in Different Legal Environments. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-11-06 Sarah Laper,Corrilynn O Hileman,Graham Block,Kristine M Erlandson,Martin Krsak
We sought to describe the prevalence of and motivation for cannabis use and whether legalization of cannabis impacts the frequency and perceived risks and benefits of use in people living with HIV (PWH). The study was based on two HIV clinics located in Cleveland, Ohio, and Aurora, Colorado. Participants responded to a 45-question survey, and responses were summarized in aggregate and stratified by
-
HIV Psychiatry: The Missing Link to HIV Prevention and Comprehensive Care. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-11-03 Mary Ann Adler Cohen,James A Bourgeois
HIV psychiatry may be the missing link to HIV prevention and care. Although HIV has been transformed from a fatal illness to a chronic and manageable illness, morbidity and mortality from HIV and AIDS continue to persist despite advances in prevention and care. In the 42 years since the HIV pandemic began in 1981, >84 million people were infected with HIV and 40 million people with HIV have died. In
-
Mpox-Related Ophthalmic Disease: A Rare Case Report. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-11-01 Maria-Alexandra Malciolu-Nica,Cristiana Costescu,Corneliu Petru Popescu,Simin Aysel Florescu,Cristiana Oprea
Monkeypox virus (mpox), a double-stranded DNA virus belonging to the Orthopox genus, can affect vulnerable anatomic sites, including the eyes, causing a monkeypox-related ophthalmic disease. The mpox virus may enter the eye via autoinoculation and cause multiple problems from mild lesions including conjunctivitis, blepharitis, keratitis, to severe ones such as corneal ulcers, corneal scarring, and
-
Perceptions of Rapid Antiretroviral Therapy Initiation Among Participants of The Netherlands Cohort Study on Acute HIV Infection. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-10-30 Pien van Paassen,Maartje Dijkstra,Holly L Peay,Casper Rokx,Annelies Verbon,Peter Reiss,Jan M Prins,Gail E Henderson,Stuart Rennie,Pythia T Nieuwkerk,Godelieve J de Bree
Starting antiretroviral therapy (ART) same-day, or as soon as possible after HIV diagnosis is advised in guidelines worldwide. Especially during acute HIV infection (AHI), rapid ART start may be more urgent because of a higher risk of transmission or symptoms of acute retroviral syndrome. During this phase, rapid ART start may have additional benefits for viral reservoir size and host immunity. We
-
Association of Fatty Acid Signatures with HIV Viremia in Pregnancy. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-10-30 Stephanie A Fisher,Jennifer K Jao,Lynn M Yee,Lena Serghides,Ellen G Chadwick,Denise L Jacobson
Omega-6 (n-6) and omega-3 (n-3) polyunsaturated fatty acids (PUFAs) are vital for fetal metabolic programming and immunomodulation. Higher n-6:n-3 ratios, reflecting a proinflammatory eicosanoid profile, are associated with adverse perinatal outcomes. Limited data exist, however, on n-6 and n-3 PUFAs specifically in the context of HIV and pregnancy. Our objective was to assess HIV clinical factors
-
Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-10-23 Alessandro Castelli,Massimiliano Lanzafame,Matteo Morra,Marco Bertoldi,Andrea Delama,Daniela Fait,Sandro Vento
The availability of long-acting cabotegravir and rilpivirine injection combination requires some changes in service delivery of outpatient HIV clinics; it is therefore important for clinicians to know the potential number of people living with HIV (PLWH) who are interested in a long-acting antiretroviral treatment. We aimed to determine in an outpatient clinic the number of PLWH, on dolutegravir/rilpivirine
-
The Role of Extracellular Traps in HIV Infection. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-10-23 Natanias Macson da Silva,Nicolas Patrícius de Medeiros Leite,Amanda Estevam Carvalho,Valéria Duarte de Almeida,Ísis Kelly Dos Santos,José Rodolfo Lopes de Paiva Cavalcanti,Thales Allyrio Araújo de Medeiros Fernandes,Ellany Gurgel Cosme do Nascimento,Micássio Fernandes de Andrade
Human immunodeficiency virus (HIV) infection is still an important public health problem, which justifies the research of new therapies to combat it. Recent studies show that Extracellular Traps (ETs) are cellular mechanisms useful in the capture and destruction of some viruses, such as the HIV. Here, we show that neutrophils from peripheral blood, genital tissues, and placenta are activated when exposed
-
No Association Between HLA-B*57:01 and Prevalence and/or Outcome of Progressive Multifocal Leukoencephalopathy in a French Nationwide Human Immunodeficiency Virus Cohort. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-10-18 Solène Secher,Maxime Hentzien,Lise Cuzin,Christine Jacomet,Laurent Hocqueloux,David Rey,Amélie Menard,Cédric Arvieux,François Raffi,Firouzé Bani-Sadr
Among 34,351 patients living with human immunodeficiency virus with available HLA-B*57:01 included in the Dat'AIDS cohort, 194 patients (0.56%) had a history of progressive multifocal leukoencephalopathy (PML) and 1,746 (5.08%) were carriers of HLA-B*57:01. The frequency of HLA-B*57:01 was similar among patients with history of PML compared with patients without a history of PML (6.19% [95% confidence
-
Using the Molecular Transmission Networks to Analyze the Epidemic Characteristics of HIV-1 CRF08_BC in Kunming, Yunnan. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-10-12 Peng Cheng,Bao-Cui He,Jia-Fa Liu,Jia-Li Wang,Cui-Xian Yang,Sha Ma,Mi Zhang,Xing-Qi Dong,Jian-Jian Li
HIV-1CRF08_BC is the most prevalent epidemic subtype among heterosexual (HET) and intravenous drug users (IDUs) in Kunming, Yunnan. Using the pol region of gene sequences derived from molecular epidemiological surveys, we developed a molecular transmission network for the purpose of analyzing its epidemiological characteristics, assessing its epidemiological trends, identifying its potential transmission
-
The Association of HIV-Specific Risk Factors with Cardiovascular Events in Addition to Traditional Risk Factors in People Living with HIV. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-10-09 Laven Mavarani,Nico Reinsch,Sarah Albayrak-Rena,Anja Potthoff,Martin Hower,Sebastian Dolff,Dirk Schadendorf,Karl-Heinz Jöckel,Börge Schmidt,Stefan Esser
Traditional cardiovascular risk scores underestimate the incidence of cardiovascular diseases (CVD) in people living with HIV (PLH). This study compared the effect of HIV-specific cardiovascular risk factors (CRF) with traditional CRF at baseline for their association with incident CVD in PLH. The ongoing, prospective HIV HEART Aging (HIVH) study assesses CVD in PLH in the German Ruhr Area since 2004
-
Molecular HIV Clustering Among Individuals with Mpox and HIV Co-Morbidity in New York State, Excluding New York City. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-09-28 Randall Collura,Thomas O'Grady,Carol-Ann Swain,Wendy Patterson,Deepa T Rajulu
The 2022 global mpox outbreak created an opportunity to test the utility of molecular HIV surveillance (MHS) to identify high-risk transmission networks. Individuals diagnosed with mpox in New York State (NYS) outside New York City-[Rest of State (ROS)] were matched to the NYS HIV and sexually transmitted infection registries. The demographic characteristics of individuals diagnosed with mpox in ROS
-
Differences in the course of CD4 and CD8 cells after chemoradiotherapy in PLWH with anal cancer. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-09-27 Gundolf Schuettfort,Caroline Roether,Annemarie Berger,Emmanouil Fokas,Ingeborg Fraunholz,Ana Groh,Annette Haberl,Pavel Khaykin,Daniel Martin,Claus Roedel,Maria Vehreschild,Christoph Stephan
BACKGROUND Incidence of anal carcinoma (AC) in people living with HIV (PLWH) is increased compared to the general population. Adverse effects of chemoradiotherapy (CRT) on the immune system are associtated with a significant detrimental prognosis on overall survival in patients receiving CRT for solid tumors. The aim of this study was to evaluate immunological factors, in particular the differences
-
Human Mpox in People Living with HIV: Epidemiologic and Clinical Perspectives from Nigeria. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-09-27 Michael O Iroezindu,Trevor A Crowell,Dimie Ogoina,Adesola Yinka-Ogunleye
Sub-Saharan Africa (SSA) is disproportionately affected by mpox and HIV. We described epidemiologic trends and clinical experiences in the management of mpox in people living with HIV (PLWH) in Nigeria and further examined how the rapidly accumulating body of knowledge from the 2022 global mpox outbreak might be explored to improve mpox care in PLWH in SSA. During the 2017/2018 Nigerian mpox outbreak
-
Evaluation of the New Multi-HTLV Serological Assay: Improvement for HTLV-2 Detection. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-09-27 Victor Ângelo Folgosi,Shirley Vasconcelos Konminakis,Felipe Dias da Silva,Pedro Domingos Leite Junior,Michel Elyas Jung Haziot,Augusto C P Oliveira,Jerusa Smid,Maan Zrein,Florent Salvador,Jorge Casseb
Despite the accuracy of confirmatory tests for the diagnosis of human T cell lymphotropic virus (HTLV), inconclusive or false-negative results still occur when diagnosing human T cell lymphotropic virus type 2 (HTLV-2)-positive patients. The goal of this study was to evaluate the sensitivity and accuracy of a confirmatory immunoassay, the Multi-HTLV assay. A total of 246 plasma samples were tested
-
Evaluation of New Hypertension Guidelines on the Prevalence and Control of Hypertension in a Clinical HIV Cohort: A Community-Based Study. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-09-07 Vishnu Priya Mallipeddi,Matthew Levy,Morgan Byrne,Anne Monroe,Lindsey Powers Happ,Letumile Rodgers Moeng,Amanda D Castel,Michael Horberg,Ronald Wilcox
The prevalence and control of hypertension (HTN) among people with HIV (PWH) have not been widely studied since the release of newer 2017 ACC/AHA guidelines ("new guidelines"). To address this research gap, we evaluated and compared the prevalence and control of HTN using both 2003 JNC 7 ("old guidelines") and new guidelines. We identified 3,206 PWH with HTN from the DC Cohort study in Washington,
-
Short Cycle, Intermittent Therapy: A Valuable Option in Selected, Virologically Suppressed People Living with HIV. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-08-31 Massimiliano Lanzafame,Emanuela Lattuada,Dora Luise,Andrea Delama,Daniela Fait,Sandro Vento
The use of long-acting antiretroviral regimens will not be suitable for all people living with HIV for various reasons (previous virological failure with drugs of the same class, side effects, logistic difficulties, and costs). We think that short-cycle therapies could represent a feasible and valuable option for antiretroviral treatment optimization in selected individuals. So here we review clinical
-
2-Hydroxyisovalerate Is Produced During Bacterial Vaginosis and Boosts HIV Infection in Resting T Cells. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-08-29 Kaitlin A Marquis,Carter Merenstein,Frederic D Bushman
Human immunodeficiency virus (HIV) infection and the ensuing acquired immunodeficiency syndrome (AIDS) disproportionally affect young women, yet understanding of the factors promoting heterosexual transmission in the female genital tract is limited. Colonization with highly diverse, Lactobacillus-deficient communities (HDCs) increases a woman's risk of acquiring HIV-1 compared with colonization with
-
Definition, Burden, and Predictors of HIV-Associated Wasting and Low Weight in the OPERA® Cohort. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-08-18 Michael B Wohlfeiler,Rachel Palmieri Weber,Laurence Brunet,Javeed Siddiqui,Michael Harbour,Amy L Phillips,Brooke Hayward,Jennifer S Fusco,Ricky K Hsu,Gregory P Fusco
We aimed to describe the prevalence, incidence, and predictors of HIV-associated wasting (HIVAW)/low weight among people with HIV (PWH) in the United States. We conducted an observational, clinical cohort analysis, utilizing prospectively collected electronic health record data obtained from the Observational Pharmaco-Epidemiology Research & Analysis (OPERA®) cohort. HIVAW/low weight included a wasting
-
Assessment of Bcl-xL, TAX, and HBZ gene expression in ATLL patients. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-08-11 Zahra Farjami,Mohammad Mehdi Akbarin,Houshang Rafatpanah,Samaneh Ramezani,Hosein Rahimi,Seyed Abdolrahim Rezaee
INTRODUCTION Adult T-cell leukemia/lymphoma is a malignancy with a poor prognosis caused by HTLV-1 infection. TAX and HBZ are two major viral proteins that may be involved in oncogenesis by disrupting apoptosis. Because Bcl-xL plays an integral role in the anti-apoptotic pathway, this study examines the interaction between host apoptosis and oncoproteins. METHOD AND MATERIAL We investigated 37 HTLV-1-infected
-
Diversity of Human T-Lymphotropic Virus Type 1 Cosmopolitan Subtype (HTLV-1a) Circulating in Infected Residents in Portugal. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-08-11 Miriam Quina,Diogo Ramos,Carolina Silva,Elizabeth Pádua
Human T-cell lymphotropic virus type 1 (HTLV-1) prevalence in Portugal is low and mainly affects immigrants from endemic areas where human immunodeficiency virus (HIV) infection represents a public health problem. Despite the majority of HTLV-1-infected individuals remains asymptomatic, severe pathologies may develop after prolonged viral persistence, namely an aggressive form of leukemia. An increased
-
MicroRNA Expression Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1 Positive Individuals and Relationship with Different Levels of Viral Suppression. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-31 Daniele Di Carlo,Francesca Falasca,Laura Mazzuti,Giuliana Guerrizio,Giuseppe Migliara,Marta Santori,Alessandro Lazzaro,Ivano Mezzaroma,Gabriella D'Ettorre,Caterina Fimiani,Giancarlo Iaiani,Guido Antonelli,Ombretta Turriziani
The persistence of low human immunodeficiency virus type 1 (HIV-1) replication in individuals undergoing antiretroviral therapy (ART) still threatens their health. Previous findings have shown that microRNAs (miRNAs) could interfere with several steps of the viral life cycle. Herein, we set out to investigate the expression of miR-150, miR-223, miR-382, miR-324-5p, miR-33a-5p, miR-34a, and miR-132
-
Mpox Infection and Sexually Transmitted Infections: A Cross-Sectional Study from a Secondary Hospital in the May-September 2022 International Outbreak. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-08-11 Javier Martínez de Victoria-Carazo,Pedro Manuel García-Ceberino,Adolfo de Salazar-González,Naya Faro-Míguez,Ana Fuentes-López,Laura Viñuela-González,Jesús Palomares-Rodríguez,Carmen Valero-Ubierna,Ricardo Ruíz-Villaverde,Federico García-García,José Hernández-Quero,Andrés Luís Ruíz-Sancho
The aims of this study were to describe the characteristics of patients infected by mpox in our setting, to determine the prevalence of mpox in samples that are classically used for diagnosing sexually transmitted infections (STIs) such as anal, urethral, pharyngeal, and urine, and to assess the prevalence of coinfection with STIs in the same samples. A cross-sectional study was conducted, collecting
-
Viral persistence in the Gut-Associated Lymphoid Tissue and barriers to HIV cure. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-14 Francesca Cossarini,Judith Aberg,Benjamin K Chen,Saurabh Mehandru
More than forty years after the first reported cases of what then became known as acquired immunodeficiency syndrome (AIDS), tremendous progress has been achieved in transforming the disease from almost universally fatal to a chronic manageable condition. Nonetheless, the efforts to find a preventative vaccine or a cure for the underlying infection with Human Immunodeficiency Virus (HIV), remain largely
-
Characteristics of Mpox Infections in Louisiana in the 2022 Outbreak. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-08-07 Nabil M Essajee,Hope Oddo-Moise,Michael E Hagensee,Rebecca A Lillis,Joanne Maffei,Isolde Butler,Aish Lovett,Theresa Sokol,Meredith E Clement
The 2022 outbreak of mpox in Louisiana was limited to just >300 cases, perhaps an unexpected outcome given the state's high rates of HIV and other sexually transmitted infections (STIs). We aimed to describe the local outbreak within two health centers in the New Orleans region, partnering with the Louisiana Department of Health to offer additional statewide data. We reviewed charts of persons testing
-
Serum Selenium and Inflammation in Individuals with Human Immunodeficiency Virus Infection. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-31 Kalpana Poudel-Tandukar,Elizabeth R Bertone-Johnson,Krishna C Poudel
HIV infection has been linked to selenium deficiency and chronic inflammation. Both selenium deficiency and inflammation have been associated with poor health outcomes among individuals with HIV. However, the role of serum selenium levels in inflammation has not been studied among individuals with HIV. We assessed the relationship of serum selenium levels to C-reactive protein (CRP), a marker of inflammation
-
Can Persistent Infections with Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, and Human T Lymphotropic Virus Type 1 Be Eradicated? AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-08-22 Sandy Vieira Teixeira,Gabriela Prates,Luiz Augusto Marcondes Fonseca,Jorge Casseb
Persistent viruses are hard to be eradicated, even using effective medications, and can persist for a long time in humans, sometimes regardless of treatment. Hepatitis B virus, hepatitis C virus, human immunodeficiency virus, and human T cell lymphotropic virus infections, the most common in our era, are still a challenge despite the increased knowledge about their biology. Most of them are highly
-
Two-Drug Regimen Containing Darunavir: Metabolic Evaluation of an Old Dual Therapy. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-08-02 Damiano Farinacci,Valentina Iannone,Anna D'Angelillo,Alberto Borghetti,Rosa Anna Passerotto,Francesco Lamanna,Simona Di Giambenedetto
Regimens containing darunavir are one of the first one with two drugs that demonstrated good efficacy as a simplification strategy. We wanted to describe the characteristics of patients followed in our center on a dual therapy regimen containing darunavir evaluating the metabolic aspects during follow-ups. We collected data from 208 patients switching to lamivudine plus darunavir with either ritonavir
-
The Burden of Pretreatment HIV Drug Resistance in Trinidad and Tobago. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-08-02 Semiu O Gbadamosi,Gregory Boyce,Mary Jo Trepka,Robert Jeffrey Edwards
Strategies to improve the scale-up of antiretroviral therapy (ART) for patients with HIV in Trinidad and Tobago, including the adoption of the "Test and Treat All" policy, have accompanied an increase in the number of patients with pretreatment HIV drug resistance (PDR) in the country. However, the scale of this public health problem is not well established. The objective of this study was to estimate
-
RFS Proudly Announces the 2022 Award Recipient for AIDS Research and Human Retroviruses. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-01 Karine Dubé
-
Perspectives on Design Approaches for HIV Prevention Efficacy Trials. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-09-04 Holly J Prudden,Roger Tatoud,Holly Janes,Stephaun Wallace,Veronica Miller,Linda-Gail Bekker,Deborah Donnell
The challenge of designing future HIV prevention efficacy trials in a rapidly evolving HIV prevention landscape was explored through a series of virtual stakeholder's engagement meetings convened online between October 2020 and April 2021. A broad array of stakeholders from the HIV prevention research community reviewed current trial designs and lessons learned, explored issues specific to unique product
-
Examining the Association Between a Modified Quan-Charlson Comorbidity Index and HIV Viral Suppression: A Cross-Sectional Analysis of DC Cohort Participants. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-27 Hasmin C Ramirez,Anne K Monroe,Morgan Byrne,Lauren F O'Connor
With the advancement of effective antiretroviral therapy, people with HIV live longer, and many are developing non-AIDS comorbidities. It is important to assess how comorbidities are associated with HIV-related health outcomes, such as viral suppression (VS). The aim of this study was to analyze the association between comorbidity burden, measured using a modified Quan-Charlson Comorbidity Index (QCCI)
-
Intracellular Islatravir-Triphosphate in Dried Blood Spots and Peripheral Blood Mononuclear Cells from Pig-Tailed Macaques. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-09-12 Vincent Mainella,Mary Morrow,Kristina Brooks,Lane Bushman,Farah Abdelmawla,David Nerguizian,Ye Ji Choi,Dorothy Patton,Yvonne Cosgrove Sweeney,Sravan Kumar Patel,Peter Anderson,Lisa Rohan
The purpose of this study was to evaluate the relationship between intracellular islatravir-triphosphate (ISL-TP) in paired peripheral blood mononuclear cells (PBMCs) and dried blood spots (DBS). Three pig-tailed macaques (PMs) were dosed with a single intravaginal extended-release ISL-etonogestrel film for a period of 31 days. After extraction and quantification, repeated measures correlation (rrm)
-
Number of Sexual Partners and Patient-Reported Outcomes Among Men Age 50+ with HIV. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-06-28 Peter Mazonson,Jeff Berko,Erik Lowman,Bruce Gilliam,Toyin Nwafor,Andrew Clark,Andrew Zolopa
Many men age 50+ with HIV (MWH age 50+) are sexually active. However, little is known about the relationship between the number of sexual partners and patient-reported outcomes in this population. To help address this need, analyses were performed on data from the Aging with Dignity, Health, Optimism and Community cohort, an observational study of adults age 50+ with HIV. Of 876 MWH age 50+, 26.8%
-
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-14 Francesca Lombardi,Elena Bruzzesi,Yagai Romeo Bouba,Domenico Di Carlo,Valentino Costabile,Martina Ranzenigo,Franco Maggiolo,Antonella Castagna,Anna Paola Callegaro,Alessia Zoncada,Stefania Paolucci,Valeria Micheli,Silvia Renica,Antonia Bezencheck,Barbara Rossetti,Maria Mercedes Santoro
Despite effective antiretroviral therapies (ARTs), a subset of people living with HIV (PLWH) still experience low-level viremia (LLV, i.e., 50-1,000 copies/mL). The present study compared PLWH experiencing LLV with those maintaining virological suppression (VS) and explored the potential impact of preexisting drug resistance and other factors on LLV. We conducted a retrospective, 1:1 matched case-control
-
Near Full-Length Genomic Characterization of Two Novel HIV Type 1 Second-Generation Recombinant Forms (CRF01_AE/CRF07_BC) from Guangxi, China. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-08-22 Meiliang Liu,Huanhuan Chen,Jianjun Li,Wenlong Cai,Haomin Xie,Guanghua Lan,Xiaoyun Zeng
CRF01_AE and CRF07_BC are the two predominant HIV-1 subtypes currently circulating in China. We identified here a novel CCR5-tropic HIV-1 second-generation recombinant form virus found in two individuals, (GX19017 and GX19032), which were isolated from two HIV-1-positive people in Guangxi, southwest China. Phylogenic analyses indicated that these two sequences were all composed of two well-established
-
Pentraxin 3 as an Immune Recovery Marker in HIV Infection After Combination Antiretroviral Therapy. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-31 Eun Hwa Lee,Jung Ah Lee,Chang Hyup Kim,Ki Hyun Lee,Jinnam Kim,Jung Ho Kim,Jin Young Ahn,Nam Su Ku,Jun Yong Choi,Joon-Sup Yeom,Su Jin Jeong
Human immunodeficiency virus (HIV) infection causes chronic inflammation in affected individuals. Chronic inflammation may hinder immunological recovery. Treatment with combination antiretroviral therapy (cART) is insufficient to reduce inflammation. Pentraxin 3 (PTX3) is an inflammatory marker associated with cardiovascular disease, malignancy, and acute infection. This study evaluated the usefulness
-
Association of Viral and Host Genetic Architecture with the Status of Neurocognitive Disorder in HIV-Infected Individuals. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-07 Sushama Jadhav,Vijay Nema
The polymorphisms in host genes such as CCR5, CCR2, stromal derived factor (SDF), and MBL (mannose-binding lectin) as well as the viral nef gene have been shown to influence human immunodeficiency virus (HIV) infection, followed by the development of HIV-associated neurocognitive disorder (HAND). In this preliminary study with a limited number of samples, we have tried to associate the genetic polymorphism
-
Genomic Characterization of a Novel HIV-1 Second-Generation Recombinant (CRF01_AE/CRF07_BC) Identified from a Men Who Have Sex with Men (MSM) Patient in Hebei, China. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-07 Huixin Cai,Jian Du,Miaomiao Su,Juan Meng,Weina An,Haoxi Shi,Weiguang Fan
Along with the co-circulation of dominant HIV-1 strains (CRF01_AE and CRF07_BC) in China, an increasing number of second-generation recombinants are being detected, especially among men who have sex with men (MSM). In this study, we identified a unique CRF01_AE/CRF07_BC recombinant from a HIV-1-positive man (BDD015A) infected through homosexual transmission in Baoding city, Hebei Province. Analysis
-
Hyperglycosylated N-Linked Site 339 of gp120 Appears to Be Unique and May Contribute to CRF01_AE Transmission Among Men Who Have Sex with Men in China and Thailand. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-06 Juan Du,Yuanlong Lin,Han Liang,Jin Li,Fuxiang Wang,Chunmei Jiang,Bing Shao
Human immunodeficiency virus (HIV)-1 CRF01_AE is one of the most important genotypes in China, especially in the population of men who have sex with men (MSM). It has become the most prevalent strain among them. Describing the variant characterization of CRF01_AE will help to reveal the reason behind its predominance in MSM. In this study, the complete DNA sequences (CDSs) for gp120 from the envelope
-
Structural Features and Genetic Diversity in Gag Gene of Rare HIV-1 Subtypes from the Democratic Republic of Congo. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-05 Célestin Godwe,Nicole Vidal,Jérémie Muwonga,Christelle Butel,Laetitia Serrano,Samuel Edidi,Steve Ahuka-Mundeke,Francioli Koro Koro,Xavier Etoa,Marcel Tongo,Martine Peeters,Ahidjo Ayouba
Type-1 HIV (HIV-1) group M (HIV-1M) genetic diversity is highest in the Congo Basin where the epidemic ignited a century ago. HIV-1M has diversified into multiple subtypes, sub-subtypes, and circulating and unique recombinant forms (CRFs/URFs). An unanswered question is why some rare subtypes never reached epidemic levels despite their age. Several studies identified the role of HIV-1M accessory genes
-
Changes of Viral Load, Drug Resistance, and CD4 Cell Count in HIV-1-Infected Patients Receiving Antiretroviral Therapy in Hebei Province, China, 2003-2019. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-05 Xinli Lu,Lin Ma,Jiayi Xu,Yan Li,Yingying Wang,Ning An,Meng Liu,Qi Li
In this study, a total of 462 samples of whole blood were collected from 36 patients enrolled. During the entire course of antiretroviral therapy (ART) from 2003 to 2019, both the CD4 cell count and viral load (VL) of study patients were examined annually, and an HIV-1 genotypic drug resistance (DR) assay was carried out using an in-house method when the HIV-1 VL was >1,000 copies/mL. The results indicated
-
Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed People Living with HIV-1 Aged Over 65 Years. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-05 Leonardo Calza,Vincenzo Colangeli,Giorgio Legnani,Silvia Cretella,Isabella Bon,Pierluigi Viale
Clinical trials of dual regimen dolutegravir/lamivudine (DOL/3TC) demonstrated potent efficacy and favorable safety in both antiretroviral therapy-naïve and -experienced patients, but data on older people are lacking. We aimed to evaluate virological efficacy and safety of DOL/3TC in suppressed older patients over a 12-month period. We performed a retrospective cohort study evaluating people living
-
Molecular and Phylogenetic Analysis of HIV-1 Subtype C in Bahia State, Northeastern Brazil. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-08-07 Rodrigo Cunha Oliveira,Juliana Sacramento Mota de Souza,Luiz Carlos Júnior Alcântara,Monick Lindenmeyer Guimarães,Carlos Brites,Joana Paixão Monteiro-Cunha
HIV-1 subtype C is associated with more than half of infections in southern Brazil and has been increasing in other regions of the country. In a previous study carried out in northeastern Brazil, we found a prevalence of 4.1% of subtype C. This work investigates the origin of subtype C in the state of Bahia based on five new viral sequences. The phylogenetic analysis showed that subtype C viruses found
-
Genomic Characteristics of the New HIV-1 CRF07_BC K28E32 Variant. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-05 Yingying Ma,Zhenzhou Wan,Min Zhang,Chiyu Zhang
Accompanied with the appearance and prevalence of the new K28E32 variant among men who have sex with men, HIV-1 circulating recombinant form 07_BC (CRF07_BC) was becoming the most predominant subtype circulating in China. The K28E32 variant with five specific mutations in reverse transcriptase coding region appears to have significantly higher in vitro HIV-1 replication ability than the wild-type strain
-
Development and Validation of a Risk Score for Predicting Non-Adherence to Antiretroviral Therapy. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-07-05 Pablo Acin,Sonia Luque,Isaac Subirana,Joan Vila,Xènia Fernández-Sala,Ana Guelar,Marta de Antonio-Cuscó,Itziar Arrieta,Hernando Knobel
Several patient-related factors that influence adherence to antiretroviral therapy (ART) have been described. However, studies that propose a practical and simple tool to predict nonadherence after ART initiation are still scarce. In this study, we develop and validate a score to predict the risk of nonadherence in people starting ART. The model/score was developed and validated using a cohort of people
-
Weight Gain in People with HIV: The Role of Demographics, Antiretroviral Therapy, and Lifestyle Factors on Weight. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-06-29 Yesha S Patel,Anjali D Doshi,Anna E Levesque,Shelsie Lindor,Robert D Moranville,Sheila C Okere,Danielle B Robinson,Lauren Taylor,Mark E Lustberg,Carlos D Malvestutto
We explored factors associated with weight gain among people with HIV (PWH) on antiretroviral therapy (ART) at The Ohio State University Wexner Medical Center (OSUWMC). This was a retrospective cohort study of adult PWH on ART for ≥3 months. Patients with CD4+ T cell count <200 cells/mm3, viral load >200 copies/mL, history of malignancy, or pregnancy were excluded. Eight hundred seventy patients met
-
Pulmonary Function and Quality of Life in Aging Men With and Without HIV from the Multicenter AIDS Cohort Study. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-06-28 Mona Abdo,Ken M Kunisaki,Alison Morris,Valentina Stosor,Dong Chang,Gypsyamber D'Souza,Kristina Crothers,Madiha Abdel-Maksoud,Carolyn DiGuiseppi,Todd T Brown,Kristine M Erlandson,Samantha MaWhinney
People living with HIV have greater pulmonary function impairments and decreased health-related quality of life (HRQoL) compared to uninfected peers. We examined whether pulmonary impairment was associated with HRQoL or respiratory health status. Using Multicenter AIDS Cohort Study data (2017-2019), associations between outcomes [HRQoL (36-Item Short Form Survey) and respiratory health status (St.
-
Chronic Kidney Disease and Accelerated Decline of Renal Function in Older Adults with HIV in Northern Thailand. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-06-26 Linda Aurpibul,Wason Paklak,Sineenart Taecharoenkul,Amaraporn Rerkasem,Kriengkrai Srithanaviboonchai
Kidney disease remains prevalent in people living with HIV even in the antiretroviral treatment era. We determine the frequency of chronic kidney disease (CKD), rate of renal function decline, and associated factors in older adults with HIV (OAHIV) aged ≥50 years in northern Thailand. We used data from the medical records and calculated the estimated glomerular filtration rate (eGFR) using the Chronic
-
Level of Antiretroviral Therapy Adherence and Associated Factors Among People Living with HIV in the Context of Early Antiretroviral Therapy Initiation in Wolaita Sodo Town, Ethiopia: Cross-Sectional Study. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-06-26 Admasu Haile Hantalo,Temesgen Tantu Arusi,Sitotaw Kolato Koche
Early antiretroviral therapy (ART) initiation is WHO recommendation to fasten viral suppression and for prevention of further viral transmission sexually. There is no evidence showing the level of adherence to ART after initiation of the universal test and treat (UTT) strategy in Ethiopia, including study area. This study was aimed to determine the level of ART adherence and associated factors among
-
Vulnerability in Biomedical Research: A Historical Reflection and Practical Implications for HIV Cure-Related Research. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-06-21 Emily Rao,Jeff Taylor,Andy Kaytes,Susanna Concha-Garcia,Patricia K Riggs,Davey M Smith,Karine Dubé,Sara Gianella
The concept of vulnerability in bioethics was first referenced in 1979, when the Belmont Report highlighted the need for special consideration of certain populations in the application of its general principles of respect for persons, beneficence, and justice in research with human participants. Since then, a body of literature has emerged regarding the content, status, and scope, as well as ethical
-
HIV-1 RNA and DNA Genotyping Drug Resistance Detection in Patients with Low-Level Viremia in Liangshan, China. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-06-27 Bianchuan Cao,Mei Liu,Tao Jiang,Qinghua Yu,Tianru Yuan,Ping Ding,Xian Zhou,Fuli Huang,Yongmao Huang,Jianning Jiang
In this study, we characterized HIV-1 RNA and HIV-1 DNA genotyping drug resistance detection in patients with low-level viremia (LLV) in Liangshan, China. Whole blood samples were collected from HIV/AIDS patients who had received antiretroviral therapy (ART) for ≥6 months and whose HIV-1 RNA loads were 50-1,000 copies/mL for two consecutive times at least 1-month apart. The patients were enrolled from
-
The Long Terminal Repeat Sequence of Subtype C and CRF01_AE Recombinants in China. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-06-26 Xing Guo,Mengying Liu,Chunlei Wang,Yanglan Wang,Hanping Li,Bohan Zhang,Yongjian Liu,Jingwan Han,Xiaolin Wang,Tianyi Li,Jingyun Li,Lei Jia,Lin Li
HIV-1 provirus is flanked by one long terminal repeat (LTR) at each terminal. The 5' LTR plays important roles in HIV-1 life cycle, especially, it determines HIV-1 transcription. However, there are 810 5' LTR entries exist in the HIV-1 sequence database, accounting for only 0.085% (810/949,484). In this study, we collected plasma samples from HIV-1-infected patients in Shenzhen province and got 219
-
Time to Virological Failure and Its Predictor Among HIV-Positive Clients with the Differentiated Service Delivery Model of HIV at Debre Berhan Comprehensive Specialized Hospital, Amhara Regional State, Ethiopia, 2021: A Retrospective Cohort Study. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-06-21 Abinet Dagnaw Mekuria,Wondesen Asegidew Meseret,Hilina Ketema Assefa,Assefa Legesse Sisay,Awraris Hailu Bilchut,Behailu Tariku Derseh,Ayele Mamo Abebe,Esubalew Tesfahun,Abebe Minda,Meseret Equbay
Diversified antiretroviral therapy (ART) approach is needed in methods that were acceptable to communities and maintain good viral suppression outcomes to reach the UNAIDS targets to end the HIV/AIDS epidemic by 2030. Ethiopia is fully implementing differentiated service delivery (DSD) approaches, appointment spacing, and standard care. This study aimed to determine the time to HIV virological failure
-
Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-06-20 Cecile D Lahiri,C Christina Mehta,Craig Sykes,Sheri D Weiser,Frank Palella,Jordan E Lake,John W Mellors,Deborah Gustafson,Audrey L French,Adaora A Adimora,Deborah Konkle-Parker,Anjali Sharma,Hector Bolivar,Seble G Kassaye,Leah H Rubin,Jessica A Alvarez,Elizabeth T Golub,Igho Ofotokun,Anandi N Sheth
Integrase strand-transfer inhibitors (INSTIs) are associated with weight gain in women living with HIV (WLH). Relationships between drug exposure, baseline obesity, and INSTI-associated weight gain remain unclear. Data from 2006 to 2016 were analyzed from virally suppressed WLH enrolled in the Women's Interagency HIV Study, who switched/added an INSTI to antiretroviral therapy: [raltegravir (RAL),
-
Mpox in a Couple Living with HIV: Relapse or Reinfection? AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-06-07 Simone Queiroz Rocha,Mylva Fonsi,Mariza Vono Tancredi,Herculano Duarte Ramos de Alencar,Adriano Abbud,Mariliza Henrique da Silva
Mpox is caused by a zoonotic orthopoxvirus capable of infecting several animal species, including humans. The analysis of cases in the current outbreak showed that, differently from what happens in the classical disease, mpox has mostly affected men who have sex with men (MSM) and bisexuals, including a high proportion of people living with HIV/AIDS. The role of the immune system in fighting mpox has
-
Lung Cancer Screening Adherence Among People with HIV Treated at an Integrated Health System in Florida. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-06-22 Jessica Y Islam,Shuang Yang,Matthew Schabath,Susan T Vadaparampil,Xiwei Lou,Yonghui Wu,Jiang Bian,Yi Guo
We evaluated low-dose computed tomography (LDCT) adherence among people with HIV (PWH) treated at University of Florida (UF). From the UF Health Integrated Data Repository, we identified PWH who underwent at least one LDCT procedure (January 1, 2012-October 31, 2021). Lung cancer screening adherence was defined as having a second LDCT within recommended observation window, based on the Lung Imaging
-
Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop Summary. AIDS Res. Hum. Retrovir. (IF 1.5) Pub Date : 2023-06-19 Brigitte E Sanders-Beer,Nancie M Archin,Zabrina L Brumme,Michael P Busch,Claire Deleage,Una O'Doherty,Stephen H Hughes,Keith R Jerome,R Brad Jones,Jonathan Karn,Mary F Kearney,Brandon F Keele,Deanna A Kulpa,Gregory M Laird,Jonathan Z Li,Mathias D Lichterfeld,Michel C Nussenzweig,Deborah Persaud,Steven A Yukl,Robert F Siliciano,John W Mellors
Since the first HIV-cured person was reported in 2009, a strong interest in developing highly sensitive HIV and SIV reservoir assays has emerged. In particular, the question arose about the comparative value of state-of-the-art assays to measure and characterize the HIV reservoir, and how these assays can be applied to accurately detect changes in the reservoir during efforts to develop a cure for